Open Access
Subscription Access
Case Report of Rare Entity for Atypical Hemolytic Uremic Syndrome
Background: Atypical Haemolytic Uremic Syndrome (aHUS) is a genetic or acquired disorder of regulatory component of the complement system. It is associated with mutations in genes coding for complement components. The abnormality in components of complement makes it susceptible and predispose to chronic uncontrolled hyperactivation of the alternative complement pathway, which results in endothelial damage and microvascular thrombosis. This case report describes a patient diagnosed with Thrombotic Microangiopathy (TMA) due to factor H autoantibody having haemolytic anemia, thrombocytopenia and acute kidney injury. Patient’s anemia and renal parameters improved after treatment with plasma exchange therapy. Conclusion: Atypical HUS must be strongly suspected in any patient who presents with nonspecific abdominal or respiratory symptoms along with anemia and thrombocytopenia. As extrarenal involvement is a rare entity of aHUS, the clinician should also keep a high index of suspicion to the possibility of thrombotic microangiopathy manifestation in almost any organ system. In a suspected or diagnosed case of aHUS, the development of new non renal symptoms and signs should prompt clinician for further evaluation to rule out ongoing thrombotic microangiopathy process.
Keywords
Acute Kidney Injury, aHUS, Complement, Dialysis, Plasma Exchange, Thrombotic-Microangiopathy (TMA)
Font Size
User
Information
- Noris M, Remuzzi G. Atypical haemolytic uremic syndrome. New England Journal of Medicine. 2009: 1676-87. https:// doi.org/10.1056/NEJMra0902814. PMid:19846853.
- Skorecki K, Chertow G. Brenner & Rector's The kidney. 10th ed. Philadelphia. Elsevier; 2016.
- Caprioli J, Noris M, Brioschi S. Genetics of HUS: The impact of MCP, CFH and IF mutation son clinical presentation, response to treatment, and outcome. Blood. 2006; 108:1267-79. https://doi.org/10.1182/blood-2005-10007252. PMid:16621965 PMCid:PMC1895874
- Loirat C, Noris M, Fremeaure-Bacchi V. Complement and the atypical haemolytic uremic syndrome in children. Pediatric Nephrology. 2008; 23(11):1957-72. https:// doi.org/10.1007/s00467-008-0872-4. PMid:18594873 PMCid:PMC6904381
- Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. New England Journal of Medicine. 2013; 368:23:2169-81. https:// doi.org/10.1056/NEJMoa1208981. PMid:23738544.
- Bakr A. Haemolytic Uremic Syndrome in Children (19552015): A 60 Years Journey. Journal of Nephrology Research. 2015; 1:2.
- Sinha A, Gulati A, Saini S. Indian HUS Registry: Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of antifactor H autoantibody associated haemolytic uremic syndrome in children. Kidney International. 2004; 85:1151-60. https://doi.org/10.1038/ ki.2013.373. PMid:24088957
- Sibai BM. Imitators of severe pre-eclapsia/eclampsia. Clinics in Perinatology. 2004; 31:835-52. https://doi.org/10.1016/j. clp.2004.06.007. PMid:15519430.
- McCrae KR, Cines DB. Thrombotic microangiopathy during pregnancy. Seminars in Hematology. 1997; 34:148.
Abstract Views: 204
PDF Views: 84